Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02389894 · ClinicalTrials.gov registry record · NA
Neuroprotection in Patients Undergoing Aortic Valve Replacement
A NA study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- NA
- Development phase
- 383
- Enrollment target
NCT02389894 is a NA study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 383 participants.
The verdict
NCT02389894, a NA study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- NA
- Development phase
- 383 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of embolic protection devices to reduce ischemic brain injury in patients undergoing surgical aortic valve replacement (AVR).
Interventions
- DEVICE Embol-X Embolic Protection Device
- DEVICE CardioGard Cannula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 383 participants |
| Start Date | 2015-03 |
| Est. Completion | 2017-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02389894
The ClinicalTrials.gov registry entry for NCT02389894 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 383 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Embol-X Embolic Protection Device is the first listed.
NCT02389894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02389894 about?
NCT02389894 is a clinical study titled "Neuroprotection in Patients Undergoing Aortic Valve Replacement". To evaluate the efficacy and safety of embolic protection devices to reduce ischemic brain injury in patients undergoing surgical aortic valve replacement (AVR).
What is the current status of trial NCT02389894?
This trial is currently completed. It is a NA study. The enrollment target is 383 participants. The study started on 2015-03. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02389894?
The interventions under investigation include: Embol-X Embolic Protection Device (DEVICE), CardioGard Cannula (DEVICE).
Who is sponsoring clinical trial NCT02389894?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.